This trial will compare no treatment to exisulind therapy. Patients enrolled on the treatment
arm will begin treatment 4 weeks prior to the scheduled date of surgical removal of the
prostate and will take 375 mg by mouth daily for the 4 weeks prior to radical prostatectomy.
Participants will be followed for total of 2 months from the time of starting study drug.